The HMGN4 Knockout Jurkat Polyclonal Cells comprise a polyclonal population of human T-lymphocyte leukemia cells engineered via CRISPR/Cas9-mediated disruption of the HMGN4 gene, generating a heterogeneous knockout model. This product is provided as a population of Jurkat cells carrying diverse loss-of-function mutations, enabling robust study of chromatin-mediated gene regulation and signal-dependent transcriptional control without clonal bias. The polyclonal format preserves cellular complexity while abrogating functional HMGN4 protein expression, making it suitable for pooled functional genomics, epigenetic drug screening, and population-level analyses of signaling pathway dynamics.
Jurkat cells are a well-characterized human acute T-cell leukemia line widely employed in immunology and cancer research. Derived from a 14-year-old male with relapsed T-cell acute lymphoblastic leukemia, these suspension cells serve as a model to interrogate T-cell receptor (TCR) signaling, apoptosis mechanisms, and viral pathogenesis, notably HIV infection. The cell line harbors defects in PTEN and SHIP-1, leading to constitutive PI3K/AKT activity, and expresses a functional TCR/CD3 complex, enabling studies of proximal TCR signaling events and downstream transcriptional responses relevant to leukemogenesis and immune cell activation.
HMGN4 encodes a nucleosome-binding protein that reduces chromatin compaction by antagonizing linker histone H1, thereby facilitating transcription factor access to DNA. This architectural protein is a key modulator of Wnt/??-catenin and NF-??B pathways: it interacts directly with NF-??B p65/p50 subunits and TCF/LEF transcription factors, and its activity is regulated upstream by mitogenic stimuli and TGF-??. HMGN4 promotes decompaction at target loci, enhancing expression of proliferation and survival genes such as CCND1, MYC, MMP9, BCL2, and BCL-XL. It cooperates with SWI/SNF chromatin remodeling complexes and is positioned within nucleosome remodeling networks that bridge signal transduction to transcriptional output.
In the Jurkat T-cell leukemia context, HMGN4 is implicated in sustaining aberrant transcription downstream of oncogenic pathways. Constitutive NF-??B activity and dysregulated Wnt/??-catenin signaling are hallmarks of T-ALL, and HMGN4 likely amplifies these programs by maintaining an open chromatin configuration at regulatory elements. Disruption of HMGN4 in this polyclonal knockout population enables dissection of how chromatin decompaction influences leukemic cell proliferation, apoptosis resistance, and signal integration, providing a physiologically relevant platform for target validation and mechanistic studies.
This knockout model supports a broad range of investigative approaches: chromatin accessibility profiling by ATAC-seq, transcriptome analysis via RNA-seq, and targeted gene expression quantification by RT-qPCR or ChIP-qPCR. Protein interaction studies through co-immunoprecipitation and Western blotting can assess HMGN4??s role in recruiting cofactors. Functional assays, including flow cytometry for proliferation and apoptosis, luciferase reporter assays for Wnt/NF-??B activity, and drug sensitivity screens, facilitate exploration of epigenetic therapies and signal transduction modulators. For more information, please contact Ascent Research.
